A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...
and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. Breaking Down Genmab's Financial Performance ...
1d
MedPage Today on MSNMixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian CancerPromising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...
AbbVie (NYSE:ABBV) disclosed:Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2023 are expected to... Effective June 29, 2023, Robert A. Michael has been appointed ...
https://www.tipranks.com/news/the-fly/genmab-says-jj-not-exercising-option-on-hexabody-cd38 Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it ...
Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, equities analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year. Analyst ...
On Tuesday, William Blair analysts revised their stance on Genmab A/S (NASDAQ:GMAB), upgrading the stock from Market Perform to Outperform. The upgrade followed Genmab’s announcement on Monday ...
Shares of GMAB stock opened at $20.21 on Tuesday. The stock has a market cap of $13.37 billion, a PE ratio of 11.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a ...
Barclays analyst Emily Field maintained a Buy rating on Genmab A/S (0MGB – Research Report) today and set a price target of DKK2,100.00. The company’s shares closed yesterday at DKK1,382. ...
2025 – Genmab A/S (Nasdaq: GMAB) held its Annual General Meeting, today at the Copenhagen Marriott Hotel, Copenhagen, Denmark. At the meeting, Deirdre P. Connelly, Chair of the Board of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results